Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q1

4574.TEDINET S100QQ1J
Period2023-01-01 → 2023-03-31
Filed2023-05-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥1.2bn2023-01-01 → 2023-03-31Cons.Net sales
Revenue¥5.0bn2022-01-01 → 2022-12-31Cons.Net sales (5-year summary)
Revenue¥621m2022-01-01 → 2022-03-31Cons.Net sales
Operating income−¥155m2023-01-01 → 2023-03-31Cons.Operating income
Operating income−¥1.7bn2022-01-01 → 2022-03-31Cons.Operating income
Ordinary income−¥242m2023-01-01 → 2023-03-31Cons.Ordinary income
Ordinary income−¥3.4bn2022-01-01 → 2022-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.7bn2022-01-01 → 2022-03-31Cons.Ordinary income
Profit before tax−¥242m2023-01-01 → 2023-03-31Cons.Income before income taxes
Profit before tax−¥1.7bn2022-01-01 → 2022-03-31Cons.Income before income taxes
Net income (owners)−¥243m2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥4.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.7bn2022-01-01 → 2022-03-31Cons.Profit loss attributable to owners of parent
Net income−¥243m2023-01-01 → 2023-03-31Cons.Profit loss
Net income−¥1.7bn2022-01-01 → 2022-03-31Cons.Profit loss
Total assets¥14.4bnat 2023-03-31Cons.Assets
Total assets¥15.0bnat 2022-12-31Cons.Assets
Total assets¥19.7bnat 2022-03-31Cons.Total assets (5-year summary)
Total liabilities¥6.5bnat 2023-03-31Cons.Liabilities
Total liabilities¥7.0bnat 2022-12-31Cons.Liabilities
Net assets / equity¥7.9bnat 2023-03-31Cons.Net assets
Net assets / equity¥8.0bnat 2022-12-31Cons.Net assets
Net assets / equity¥11.1bnat 2022-03-31Cons.Net assets (5-year summary)
Cash and deposits¥3.1bnat 2023-03-31Cons.Cash and deposits
Cash and deposits¥3.1bnat 2022-12-31Cons.Cash and deposits
EPS (basic)¥-5.592023-01-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-112.262022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-40.132022-01-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio54.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio53.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio56.4%at 2022-03-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥241m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥259m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥259m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentsegment profit2023-01-01 → 2023-03-31−¥124m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue2023-01-01 → 2023-03-31¥1m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue external2023-01-01 → 2023-03-31¥1m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentsegment profit2023-01-01 → 2023-03-31−¥5m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥906m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥906m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-03-31¥215m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-03-31¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-03-31¥1.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-03-31¥85m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-03-31−¥360m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-03-31¥39m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-03-31¥39m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-03-31−¥1.3bn
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue2022-01-01 → 2022-03-31¥2m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue external2022-01-01 → 2022-03-31¥2m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentsegment profit2022-01-01 → 2022-03-31−¥6m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-03-31¥579m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-03-31¥579m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-03-31¥13m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-03-31¥621m
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-03-31¥621m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-03-31−¥1.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 339
ItemContextValueUnit
Income taxes payablePrior1YearInstant17000000JPY
Income taxes payableCurrentQuarterInstant8000000JPY
Refund liabilities clPrior1YearInstant94000000JPY
Refund liabilities clCurrentQuarterInstant77000000JPY
Provision for bonusesPrior1YearInstant23000000JPY
Provision for bonusesCurrentQuarterInstant29000000JPY
Provision for surcharge clPrior1YearInstant607000000JPY
Provision for surcharge clCurrentQuarterInstant607000000JPY
Other clPrior1YearInstant181000000JPY
Other clCurrentQuarterInstant161000000JPY
Current liabilitiesPrior1YearInstant2793000000JPY
Current liabilitiesCurrentQuarterInstant2625000000JPY
Long term loans payablePrior1YearInstant2720000000JPY
Long term loans payableCurrentQuarterInstant2460000000JPY
Long term accounts payable otherPrior1YearInstant549000000JPY
Long term accounts payable otherCurrentQuarterInstant549000000JPY
Net defined benefit liabilityPrior1YearInstant659000000JPY
Net defined benefit liabilityCurrentQuarterInstant639000000JPY
Other nclPrior1YearInstant279000000JPY
Other nclCurrentQuarterInstant272000000JPY
Noncurrent liabilitiesPrior1YearInstant4208000000JPY
Noncurrent liabilitiesCurrentQuarterInstant3921000000JPY
LiabilitiesPrior1YearInstant7001000000JPY
LiabilitiesCurrentQuarterInstant6547000000JPY
Capital stockPrior1YearInstant1201000000JPY
Capital stockCurrentQuarterInstant1219000000JPY
Capital surplusPrior1YearInstant1642000000JPY
Capital surplusCurrentQuarterInstant1659000000JPY
Retained earningsPrior1YearInstant5239000000JPY
Retained earningsCurrentQuarterInstant4995000000JPY
Treasury stockPrior1YearInstant-348000000JPY
Treasury stockCurrentQuarterInstant-348000000JPY
Shareholders equityPrior1YearInstant7734000000JPY
Shareholders equityCurrentQuarterInstant7526000000JPY
Foreign currency translation adjustmentPrior1YearInstant309000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant318000000JPY
Valuation and translation adjustmentsPrior1YearInstant309000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant318000000JPY
Subscription rights to sharesPrior1YearInstant－JPY
Subscription rights to sharesCurrentQuarterInstant12000000JPY
Net assetsPrior1YearInstant8044000000JPY
Net assetsCurrentQuarterInstant7857000000JPY
Liabilities and net assetsPrior1YearInstant15046000000JPY
Liabilities and net assetsCurrentQuarterInstant14404000000JPY
Net salesPrior1YTDDuration621000000JPY
Net salesCurrentYTDDuration1167000000JPY
Cost of salesPrior1YTDDuration1161000000JPY
Cost of salesCurrentYTDDuration593000000JPY
Gross profitPrior1YTDDuration-540000000JPY
Gross profitCurrentYTDDuration574000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass